As part of International Kissing Day on July 6, the Restylane brand announces the results of a first-of-its-kind phase IV, Kissability study of Restylane Kysse, its injectable hyaluronic acid (HA) lip filler.
The study evaluated not only subject satisfaction but, reportedly for the first time, partner satisfaction following treatment. According to the Kissability study, 100% of the participants and 90% of their partners were satisfied with their lips after Restylane Kysse treatment, with most partners (73%) reporting a more kissable and natural feel.
The phase IV Kissability data also found that subjects agreed that their lips had a natural look (96%) and that they felt more attractive (87%) after treatment with Restylane Kysse. In addition, 98% of subjects also reported they were satisfied with the kissability of their lips after treatment.
“The creative and unique approach to this phase IV study design has allowed the Restylane brand to distinctively showcase and amplify the data from both the patient and the partner perspectives,” Alisa Lask, General Manager and Vice President of the U.S. Aesthetics Business at Galderma, says in a media release.
“The phase IV Kissability study helps answer the ongoing question from patients to their aesthetic provider: ‘How will my partner react?’ The data from this study supports that Restylane Kysse resulted in overwhelmingly positive partner satisfaction with both kissability and appearance,” adds Dr Janelle Vega, board-certified dermatologist and paid Galderma consultant in Miami. “The use of XpresHAn Technology in Restylane Kysse helps patients look more natural when they are smiling, speaking, laughing, and even kissing – right in time for International Kissing Day!”
All subjects in the Restylane Kysse phase IV study were over the age of 21, in a steady relationship with a partner for at least 6 months, and had the intent to undergo lip augmentation. Completed separately by the subject and their partners, at home, the Kissability Questionnaire explored how satisfied partners were with subjects’ lips after injection, and if they were even more kissable.
Primary endpoints included subject-assessed Global Aesthetic Improvement Scale (GAIS) at week 8 and secondary endpoints included independent photographic review of naturalness of expression, age, and lip texture, adverse events (AEs), FACE-Q satisfaction with lips (subject) and Kissability questionnaire (between visits), the release continues.
Galderma is working closely with their aesthetic healthcare provider partners, while following all safe and proper social distancing guidelines, to offer Restylane Kysse in healthcare providers’ respective practice locations across the country.
[Source(s): Galderma, PR Newswire]